Meridian Medical Technologies has signed a USD $129m contract to supply its chemical nerve agent antidote autoinjector, DuoDote to the Strategic National Stockpile (SNS).
The global health security division of Kindeva Drug Delivery will provide the dual-chamber autoinjector to assist the SNS CHEMPACK programme (the US's emergency preparedness programme), which aims to protect civilians from chemical nerve agent attacks.
DuoDote is suitable for the treatment of poisoning by organophosphorus nerve agents and insecticides.
Under the terms of the agreement, Kindeva will be responsible for the manufacture of DuoDote in the US, which will be distributed and stockpiled in strategic locations across the country.
The company will utilise its fill/finish facility in St Louis, Missouri to achieve this.
Milton Boyer, CEO of Kindeva, commented: “Kindeva is a global force in medical countermeasure development, manufacturing and supply. As a trusted partner to the SNS, this contract underscores the ongoing importance of maintaining readiness against potential threats.”
“Our long-standing partnership with the SNS reflects our commitment to national preparedness and our ability to deliver crucial medical countermeasures when they are needed most."
"With our experience in this space, we are proud to continue supporting the US government’s efforts to protect public health and safety.” he concluded.